Brendan M. Everett
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
2017/08/27 by Paul M. Ridker, Brendan M. Everett, Tom Thurén +25 · 9,315 citations
Biochemistry, Genetics and Molecular Biology · Medicine · Immunology and Microbiology · #Inflammasome and immune disorders #Adipokines, Inflammation, and Metabolic Diseases #Atherosclerosis and Cardiovascular Diseases #Canakinumab #Medicine #Placebo #Myocardial infarction #Hazard ratio #Internal medicine #Confidence interval #Randomized controlled trial #Clinical endpoint #C-reactive protein #Surgery #Gastroenterology #Inflammation #Disease #Pathology #Anakinra
- Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
2018/11/10 by Paul M. Ridker, Brendan M. Everett, Aruna D. Pradhan +23 · 1,312 citations
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · Medicine · #Inflammasome and immune disorders #Atherosclerosis and Cardiovascular Diseases #Rheumatoid Arthritis Research and Therapies #Methotrexate #Medicine #Internal medicine
- Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations
2026/03/04 by John W. Ostrominski, Janinne Ortega-Montiel, Deborah J. Wexler +6 · 1 voice
Medicine · #Diabetes Management and Research #Diabetes Treatment and Management #Diabetes, Cardiovascular Risks, and Lipoproteins